CANCER:

Rectal Cancer

Related cancers:

‹

Colorectal Cancer (1050)

Colon Cancer (115)

Colorectal Adenocarcinoma (7)

Colorectal Cancer (1050)

Colon Cancer (115)

Colorectal Adenocarcinoma (7)

›

No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRI Sensitive: A1 - Approval	FOLFIRI Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	irinotecan Sensitive: A1 - Approval	irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRINOX Sensitive: A2 - Guideline	FOLFIRINOX Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFOX Sensitive: A2 - Guideline	FOLFOX Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	CAPOX Sensitive: A2 - Guideline	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: A2 - Guideline	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	trifluridine/tipiracil Sensitive: A2 - Guideline	trifluridine / tipiracil Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline	trastuzumab + pertuzumab Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline	trastuzumab + lapatinib Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	NTRK1 fusion NTRK1 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline	cetuximab + encorafenib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	BRAF V600 BRAF V600	Rectal Cancer Rectal Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline	panitumumab + encorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	ramucirumab Sensitive: A2 - Guideline	ramucirumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	ziv-aflibercept IV Sensitive: A2 - Guideline	ziv-aflibercept IV Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	mFOLFOX6 Sensitive: A2 - Guideline	mFOLFOX6 Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	regorafenib Sensitive: A2 - Guideline	regorafenib Sensitive: A2 - Guideline
UGT1A111 UGT1A111	Rectal Cancer Rectal Cancer	UGT1A111 UGT1A111	Rectal Cancer Rectal Cancer	capecitabine + irinotecan Sensitive: B - Late Trials	capecitabine + irinotecan Sensitive: B - Late Trials
No biomarker No biomarker	Rectal Cancer Rectal Cancer	No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRINOX + mFOLFOX6 Sensitive: B - Late Trials	FOLFIRINOX + mFOLFOX6 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Rectal Cancer Rectal Cancer	PD-L1 expression PD-L1 expression	Rectal Cancer Rectal Cancer	nivolumab Sensitive: C1 - Off-label	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	sintilimab Sensitive: C2 – Inclusion Criteria	sintilimab Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Rectal Cancer Rectal Cancer	BRAF mutation BRAF mutation	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria	bevacizumab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Rectal Cancer Rectal Cancer	TMB-H TMB-H	Rectal Cancer Rectal Cancer	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	5-fluorouracil Resistant: C3 – Early Trials	5-fluorouracil Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	FOLFOX Resistant: C3 – Early Trials	FOLFOX Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	CAPOX Resistant: C3 – Early Trials	CAPOX Resistant: C3 – Early Trials
TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	TACC3 expression TACC3 expression	Rectal Cancer Rectal Cancer	capecitabine Resistant: C3 – Early Trials	capecitabine Resistant: C3 – Early Trials
AFP elevation AFP elevation	Rectal Cancer Rectal Cancer	AFP elevation AFP elevation	Rectal Cancer Rectal Cancer	mFOLFOX6 Sensitive: C3 – Early Trials	mFOLFOX6 Sensitive: C3 – Early Trials
EZH2 underexpression EZH2 underexpression	Rectal Cancer Rectal Cancer	EZH2 underexpression EZH2 underexpression	Rectal Cancer Rectal Cancer	capecitabine Sensitive: C3 – Early Trials	capecitabine Sensitive: C3 – Early Trials
RUNX3 overexpression RUNX3 overexpression	Rectal Cancer Rectal Cancer	RUNX3 overexpression RUNX3 overexpression	Rectal Cancer Rectal Cancer	capecitabine Sensitive: C3 – Early Trials	capecitabine Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Rectal Cancer Rectal Cancer	KRAS mutation KRAS mutation	Rectal Cancer Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials	SOXIRI Sensitive: C3 – Early Trials
NRAS mutation NRAS mutation	Rectal Cancer Rectal Cancer	NRAS mutation NRAS mutation	Rectal Cancer Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials	SOXIRI Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials	SOXIRI Sensitive: C3 – Early Trials
NRAS mutation NRAS mutation	Rectal Cancer Rectal Cancer	NRAS mutation NRAS mutation	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials	FOLFOXIRI Sensitive: C3 – Early Trials
HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	HRAS mutation HRAS mutation	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials	FOLFOXIRI Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Rectal Cancer Rectal Cancer	KRAS mutation KRAS mutation	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials	FOLFOXIRI Sensitive: C3 – Early Trials
KRAS mutation + ATM mutation KRAS mutation + ATM mutation	Rectal Cancer Rectal Cancer	KRAS mutation + ATM mutation KRAS mutation + ATM mutation	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: C4 – Case Studies	bevacizumab Sensitive: C4 – Case Studies
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	ipilimumab Sensitive: C4 – Case Studies	ipilimumab Sensitive: C4 – Case Studies
RAS wild-type + BRAF wild-type RAS wild-type + BRAF wild-type	Rectal Cancer Rectal Cancer	RAS wild-type + BRAF wild-type RAS wild-type + BRAF wild-type	Rectal Cancer Rectal Cancer	panitumumab Sensitive: C4 – Case Studies	panitumumab Sensitive: C4 – Case Studies
PAI1 expression PAI1 expression	Rectal Cancer Rectal Cancer	PAI1 expression PAI1 expression	Rectal Cancer Rectal Cancer	AZD1208 Sensitive: D – Preclinical	AZD1208 Sensitive: D – Preclinical

Rectal Cancer

Associations(53)

Associations
(53)